Anaerobic Power and Salbutamol

University of British Columbia

Status: Completed

Conditions: Ergogenic Athletic Performance

Treatments: Other: Cycling Exercise

Study type: Interventional

Funder types: Other

Identifiers

NCT02255630

H14-02788

Details and patient eligibility

About

Athletes using inhaled β2-adrenoreceptor agonists (IBAs) win a disproportionate number of medals. However, most previous research has shown that β2 agonists do not improve exercise performance in either asthmatic or non-asthmatic athletes. Although the majority of these studies do not show an ergogenic effect, the small number of studies with extended exercise bouts (~60 minutes) do show an advantage. The investigators believe that a controlled yet sport-specific exercise protocol will elucidate this ergogenic effect. Because IBAs may have different effects on these two groups of athletes, the investigators will measure exercise performance in both female and male elite cyclists. The investigators hypothesize that athletes will perform better during a combination steady-state/sprint exercise task following salbutamol administration.

Enrollment: 20 patients

Sex: All

Ages: 19 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• maximal oxygen consumption of ≥60 and ≥55 mL⋅kg-1⋅min-1 or ≥5⋅L⋅min-1 and ≥4⋅L⋅min-1 for men and women

Exclusion criteria

• pregnant women
• any history of uncontrolled respiratory or cardiac disease
• smokers
• diabetics

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

20 participants in 2 patient groups

Salbutamol inhalation

Experimental group

Description:

Study participants will be exposed to 1600ug salbutamol 30min prior to exercise

Treatment:

Other: Cycling Exercise

Placebo inhalation

Experimental group

Description:

Study participants will be exposed to 1600ug salbutamol 30min prior to exercise

Treatment:

Other: Cycling Exercise